JP2025515029A - 血管透過性の選択的調節のための組成物及び方法 - Google Patents

血管透過性の選択的調節のための組成物及び方法 Download PDF

Info

Publication number
JP2025515029A
JP2025515029A JP2024564653A JP2024564653A JP2025515029A JP 2025515029 A JP2025515029 A JP 2025515029A JP 2024564653 A JP2024564653 A JP 2024564653A JP 2024564653 A JP2024564653 A JP 2024564653A JP 2025515029 A JP2025515029 A JP 2025515029A
Authority
JP
Japan
Prior art keywords
amino acid
seq
cdr1
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515029A5 (cg-RX-API-DMAC7.html
Inventor
ゼボ クリスティーナ
ジェイ. ダッカーズ ヘンリカス
Original Assignee
ブイエスティー バイオ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブイエスティー バイオ コーポレーション filed Critical ブイエスティー バイオ コーポレーション
Publication of JP2025515029A publication Critical patent/JP2025515029A/ja
Publication of JP2025515029A5 publication Critical patent/JP2025515029A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024564653A 2022-05-04 2023-05-03 血管透過性の選択的調節のための組成物及び方法 Pending JP2025515029A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263338359P 2022-05-04 2022-05-04
US63/338,359 2022-05-04
US202363444520P 2023-02-09 2023-02-09
US202363444521P 2023-02-09 2023-02-09
US63/444,520 2023-02-09
US63/444,521 2023-02-09
US202363495763P 2023-04-12 2023-04-12
US202363495765P 2023-04-12 2023-04-12
US63/495,765 2023-04-12
US63/495,763 2023-04-12
PCT/US2023/066549 WO2023215787A1 (en) 2022-05-04 2023-05-03 Compositions and methods for selective regulation of vascular permeability

Publications (2)

Publication Number Publication Date
JP2025515029A true JP2025515029A (ja) 2025-05-13
JP2025515029A5 JP2025515029A5 (cg-RX-API-DMAC7.html) 2026-05-15

Family

ID=88647182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564653A Pending JP2025515029A (ja) 2022-05-04 2023-05-03 血管透過性の選択的調節のための組成物及び方法

Country Status (4)

Country Link
US (1) US20250282885A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519320A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515029A (cg-RX-API-DMAC7.html)
WO (1) WO2023215787A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
JP2023537452A (ja) * 2020-05-22 2023-09-01 イエール ユニバーシティ 血管漏出を処置するための方法および組成物
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2023215787A8 (en) 2024-11-14
EP4519320A1 (en) 2025-03-12
US20250282885A1 (en) 2025-09-11
WO2023215787A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US11680100B2 (en) B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
JP6843868B2 (ja) Pd−1結合タンパク質及びその使用方法
US20210069325A1 (en) Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) Methods of treating vitiligo using PD-1 binding antibodies
EP3882268A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
US7371381B2 (en) Anti-galanin antibodies and uses thereof
CN102300997B (zh) Toll样受体3拮抗剂
KR20240128132A (ko) 중화 항-tl1a 단일 클론 항체
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
WO2020063660A1 (zh) 抗ox40抗体、其抗原结合片段及其医药用途
JP7672532B2 (ja) アイソフォーム選択的抗tgf-ベータ抗体及び使用方法
JP2023510787A (ja) 抗angptl3抗体及びその応用
JP2026081251A (ja) 抗trem-1抗体およびその使用
US20250282885A1 (en) Compositions and methods for selective regulation of vascular permeability
EP3990490A1 (en) Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof
JP2024507823A (ja) 免疫監視を増強するために制御性t細胞を標的化するための材料及び方法
WO2022256739A2 (en) Antibody specific for bcl-6 and methods of use
WO2025101747A1 (en) Methods and compositions for treatment of pulmonary hypertension
WO2025201517A1 (zh) 抗cd93抗体、其抗原结合片段及其应用
WO2026030235A1 (en) Methods and compositions for treatment of cytokine release syndrome
HK40045560A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501